Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis

Company Overview

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $18.50 to $19.75
• 50-Day Range: $16.26 to $21.03
• 52-Week Range: $7.48 to $29.82
• Volume: 250,153 shs
• Average Volume: 212,231 shs
• Market Capitalization: $336.08 million
• P/E Ratio: 134.37
• Dividend Yield: N/A
• Price Target: $36.40
• Consensus Rating: Hold

Rigel Pharmaceuticals Stock Analysis - MarketRank™

Rigel Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 489th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Rigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Rigel Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 377.27%

Earnings Growth

Earnings for Rigel Pharmaceuticals are expected to grow by 377.27% in the coming year, from $0.22 to $1.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rigel Pharmaceuticals is 134.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.23.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rigel Pharmaceuticals is 134.37, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.05.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.70% of the float of Rigel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in Rigel Pharmaceuticals has recently increased by 2.76%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rigel Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rigel Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.70% of the float of Rigel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in Rigel Pharmaceuticals has recently increased by 2.76%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.66

News Sentiment

Rigel Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 35 news articles for Rigel Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for RIGL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.48% of the stock of Rigel Pharmaceuticals is held by insiders.

Percentage Held by Institutions

66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RIGL Stock Analysis - Frequently Asked Questions

How have RIGL shares performed this year?

Rigel Pharmaceuticals' stock was trading at $16.82 at the beginning of 2025. Since then, RIGL stock has increased by 11.8% and is now trading at $18.81.
View the best growth stocks for 2025 here.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings results on Tuesday, May, 6th. The biotechnology company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.49. The biotechnology company had revenue of $53.33 million for the quarter, compared to analysts' expectations of $43.87 million. Rigel Pharmaceuticals had a negative trailing twelve-month return on equity of 14.80% and a net margin of 2.46%.
Read the conference call transcript.

When did Rigel Pharmaceuticals' stock split?

Rigel Pharmaceuticals's stock reverse split on the morning of Thursday, June 27th 2024. The 1-10 reverse split was announced on Thursday, June 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' top institutional investors include Vanguard Group Inc. (5.75%), Assenagon Asset Management S.A. (2.93%), CM Management LLC (1.40%) and Pacer Advisors Inc. (0.63%). Insiders that own company stock include Raul R Rodriguez, Dean L Schorno and David A Santos.
View institutional ownership trends.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rigel Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), SPDR S&P 500 ETF Trust (SPY) and CRISPR Therapeutics (CRSP).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 5/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RIGL
• CIK: 1034842
• Web: www.rigel.com
• Phone: (650) 624-1100
• Fax: 650-624-1101
• Employees: 160
• Year Founded: 1996

Price Target and Rating

• Average Stock Price Target: $36.40
• High Stock Price Target: $57.00
• Low Stock Price Target: $23.00
• Potential Upside/Downside: +93.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.07
• Trailing P/E Ratio: 134.37
• Forward P/E Ratio: 85.50
• P/E Growth: N/A
• Net Income: $-25,090,000.00
• Net Margins: 2.46%
• Pretax Margin: 2.46%
• Return on Equity: -14.80%
• Return on Assets: 3.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.96
• Quick Ratio: 1.87

Sales & Book Value

• Annual Sales: $179.28 million
• Price / Sales: 1.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.64) per share
• Price / Book: -11.47

Miscellaneous

• Outstanding Shares: 17,867,000
• Free Float: 16,023,000
• Market Cap: $336.08 million
• Optionable: Optionable
• Beta: 1.34